Company Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.
It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis.
Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola.
The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009.
Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jun 15, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Christopher Schaber |
Contact Details
Address: 29 Emmons Drive, Suite B-10 Princeton, New Jersey 08540 United States | |
| Phone | 609 538 8200 |
| Website | soligenix.com |
Stock Details
| Ticker Symbol | SNGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000812796 |
| CUSIP Number | 834223307 |
| ISIN Number | US8342235053 |
| Employer ID | 41-1505029 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Schaber Ph.D. | Chairman of the Board of Directors, Chief Executive Officer and President |
| Jonathan L. Guarino CPA, CGMA | Senior Vice President, Chief Financial Officer and Corporate Secretary |
| Dr. Oreola Donini Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Richard C. Straube M.D., MSc. | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | ARS | Filing |
| May 5, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 5, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 26, 2025 | EFFECT | Notice of Effectiveness |
| Mar 26, 2025 | EFFECT | Notice of Effectiveness |
| Mar 26, 2025 | EFFECT | Notice of Effectiveness |
| Mar 21, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 21, 2025 | POS AM | Post-Effective amendments for registration statement |